May 30, 2020
No OS Boost With Opdivo in Recurrent Glioblastoma BookmarkGeorge Lundberg, MD
Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
April 21, 2020
5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery BookmarkGeorge Lundberg, MD
Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes:
The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.
February 22, 2020
Predicting Prognosis in Glioblastoma BookmarkGeorge Lundberg, MD
Article from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes:
Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).
February 22, 2020
Data Favor Max Resection for All Glioblastomas BookmarkGeorge Lundberg, MD
Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.
December 2, 2019
Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma Patients BookmarkGeorge Lundberg, MD
Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes:
This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.
September 16, 2019
George Lundberg, MD
A Q&A with Burt Nabors, MD, Professor and Director of the Division of Neuro-oncology at the University of Alabama, Birmingham, and a member of the Cancer Commons Brain Tumor Advisory Board; firstname.lastname@example.org Q: Primary brain gliomas can be devastating, often deadly, malignancies. Obvious prognostic factors include whether they are grade 1, 2, 3, or 4; their extent of growth prior to diagnosis (stage); and… Read more »
August 26, 2019
A Q&A with Anita Hjelmeland, PhD, Associate Professor of Cell, Developmental and Integrative Biology at the University of Alabama Birmingham School of Medicine; email@example.com Q: The inner workings of malignant gliomas are mysterious to many of us. Why does the prognosis of patients with these tumors remain poor? A: Glioblastoma is a primary brain tumor that is treated with surgery, radiation, and chemotherapy. While… Read more »